Filip Poelaert

MD PhD FEBU -
Urologist @ZAS_Ziekenhuis

[De Specialist @specialistkrant]

Zo wil het RIZIV de artsenhonoraria opsplitsen: 65% intellectueel, 35% praktijkkosten - https://t.co/POzFmNFCq3 @bvastweets @ASGB_KARTEL @GevaertThomas @dr_wardsam @DeClercqLuc @BOVYN

[De Specialist @specialistkrant]

Thomas Gevaert slaat alarm over splitsing honorarium: "Arts blijft geen eigenaar van het kostendeel”  - https://t.co/65O58POGwt @ASGB_KARTEL @GevaertThomas

[De Specialist @specialistkrant]

Marc Moens over de splitsing van het honorarium: “Ik vrees dat de artsen in een valstrik zijn getrapt” - https://t.co/mBkaAMg0mk @MarcMoens50 @bvastweets @ASGB_KARTEL

[Kari Tikkinen @KariTikkinen]

🔥 POISE-3 Urology published in European Urology 🚨

In the largest randomized placebo-controlled #urology analysis of #TranexamicAcid (TXA), #TXA reduced major #bleeding risk by 37% (from 9.5% to 6.1%) with no clear increase in #thrombosis

More at https://t.co/Yypy7vb9Jz

#EBM

[Zach Klaassen @zklaassen_md]

#SESAUA26 State of the Art Lecture @sanojpunnen

PCa Screening Guidelines:
♦️Start: 45-50 yrs
♦️Screen q2-4 yrs if PSA < 1
♦️Screen q1-2 yrs if PSA >1
♦️Intervene: PSA 3-4
♦️Stop: 70-75 yrs or life expectancy < 10 yrs

@urotoday

[Karl Tan, MD (Endouro) 🇵🇭 @iamdockarl]

Impact of 1g Tranexamic Acid on Outcomes in EEP Patients
🩸 Reduced bleeding complications with TXA (OR 0.17)
⏲ Shortest hemostasis time with TXA (p < 0.001)
📈 Higher bleeding risk on blood thinners (OR 2.93)

@DocGauhar @trwherrmann @ytanidir @drabhaymahajan @doc_sarvajit @endouro @D_Castellani @steffiyuen

[Adam B. Weiner, MD @Adam_Weiner535]

🌍 Global patient reported outcomes (PROs) after localized #ProstateCancer treatment

👇New data from 27,499 patients across 16 countries (TrueNTH Registry)

Big predictors
🏁 Baseline function matters most
🏥 Treatment modality drives domain-specific tradeoffs

12-mo outcomes
🔴 RP → ↓ urinary continence & sexual function
📡 EBRT + ADT → ↓ bowel & hormonal function
🟢 AS → smallest functional declines

Reality check
⚠️Global models explain only ~14–32% of variance
🌐 Major regional heterogeneity → one-size models fall short

🎯 Takeaway
Personalized counseling needs baseline function + local context, not just treatment labels

🔗https://t.co/OQzEaGpoUi

@UCLAHealthJCCC @UclaUrology @CS_Urology @CSCancerCenter @UrologyTimes @PCFnews @renalandurology @urotoday

[Mario Balsa @MarioBalsaMD]

🚨 New ESMO guideline on localized & locoregional prostate cancer! https://t.co/lpDweqBiUn

💥 Clear algorithms for diagnosis, risk stratification & treatment
🎯 Active surveillance where appropriate & escalation when needed
🤝 Multidisciplinary (evidence-based) globally aligned

Good oncology isn’t about doing more…it’s about doing it right!!

Congrats to @AttardLab @Ecastromarcos @stefanofanti4 @Silke_Gillessen @Prof_Nick_James @piet_ost @MarkARubin1 @ChrisSweens1 @Tilki_De @ZilliThomas @alison_tree and all the team! 👏🏼

@OncoAlert #OncoAlertAF @OncoReporte @myESMO @_SEOM

[Dries Develtere @DriesDeveltere]

PSA for Prostate Cancer Screening: How ERSPC confirms the importance of active surveillance https://t.co/8A3NGsiudO

[Adam B. Weiner, MD @Adam_Weiner535]

🤖🆚🗡️ Robotic vs open partial nephrectomy for complex kidney tumors

👏Tested in an RCT (OpeRa trial)

@Annals_Oncology

🔑🔑 Takeaways:

⚖️ 30-day complications: no significant difference (RAPN 37% vs OPN 46%)
⏱️ RAPN = longer OR + warm ischemia time
🏥 RAPN = shorter hospital stay
💊 Less opioids, less pain
😊 Better QoL through POD30

⭐️ RAPN not clearly safer, but easier on patients in the short term — even for intermediate/high-complexity tumors

🔗https://t.co/bVnRZKb8yt

@urotoday @renalandurology @UrologyTimes

[De Specialist @specialistkrant]

Hoeveel verdienen ASO’s na indexering? - https://t.co/VFg5OJYx3f @TweetsVaso @bvastweets @ASGB_KARTEL

[De Specialist @specialistkrant]

Transparantiecodes en pseudocodes: wat u werkelijk codeert - https://t.co/pVb5Ld5LQy

[Juan Gómez Rivas @JGomezRivas]

✨ New evidence in high-risk prostate cancer staging! ✨

A large multi-institutional study from @Uroweb Young Academic Prostate Cancer group shows that patients staged with PSMA-PET before surgery experience better short-term oncologic outcomes than those staged with conventional imaging.

📌 Key highlights:
✔️ Lower PSA persistence rates
✔️ Higher biochemical recurrence-free survival at 36 months (90.9% vs 82.2%)
✔️ PSMA-PET was an independent predictor of improved outcomes

➡️ These results underscore the importance of accurate preoperative staging to guide treatment and patient selection.

🔍 Full citation: https://t.co/Pqhiabnv8T

#ProstateCancer #Urology

@EAU_YAUProstate @dr_rajwa @GGandaglia @NICOLETTIRosse1

[Nikolas De Meurechy @NDeMeurechy]

Het is duidelijk uit de analyses van de laatste dagen, alsook uit de discussies in de plenaire en de commissie dat de Kaderwet geen afgeronde zaak is.

Juridisch zijn er enkele hete hangijzers en de inhoudelijke ideologische supplexen die er uitgevoerd worden zijn niet te negeren. Dankzij de evenredigheidsrichtlijn krijgen we als zorgverleners nu de kans om te reageren en ons bezwaar te uiten, zonder dat onze patiënten , noch de praktijkwerking hiervan de dupe hoeft te zijn.

Met deze website heb ik de verschillende templates voor bezwaren proberen te bundelen, zodat deze vlot beschikbaar zijn en je deze naar eigen wens kan aanpassen dankzij het Word-format. Wie wil kan ook zijn RIZIV-nr achterlaten, zodat we kunnen opvolgen hoeveel inzendingen er zijn.

Dit is niet zonder belang want meerdere politieke actoren hebben al duidelijk gemaakt dat indien er een groot aantal inzendingen zijn, hier toch iets met gedaan zal moeten worden. Het is eveneens duidelijk dat het kabinet geen zin had in deze bevraging, gezien ze dit pas hebben uitgeschreven op dwingende vraag van een juridisch advies en daarbij zelfs de minimale tijdsduur van 8 weken niet respecteren (mi. is het RIZIV lijdend voorwerp in deze). Uw bezwaar insturen kan dus zéér zeker een verschil maken.

Spoor daarom ook uw collega's, uw medische raad, uw beroepsgroep,... aan om een bezwaar in te sturen en breng deze site onder aandacht bij uw collega's!

https://t.co/Thw9K45onD

@SGeysenbergh @josvanhoof1957 @BLANCKAERTJoha1 @DeClercqLuc @frederik_kao @BOVYN @theharleydoc @GevaertThomas @daviddesmetmed @DanBacquelaine @ancapoen @catherinefonck @FriedaGijbels @louis_ide @KDepoorterMP @ASGB_KARTEL @bvastweets @DominiekSneppe @IrinaDeKnop

[De Specialist @specialistkrant]

Artsen krijgen eindelijk houvast om te reageren op de kaderwet - https://t.co/xOUpZI2qF2 @NDeMeurechy @GevaertThomas @DeClercqLuc @BLANCKAERTJoha1 @dr_wardsam @bvastweets @ASGB_KARTEL

[NEJM @NEJM]

At 23 years of follow-up, population-based PSA screening of asymptomatic men led to a sustained reduction in prostate cancer mortality, although overdiagnosis remains a concern. Full ERSPC study results: https://t.co/iwULrhSglD

Editorial: Early Detection of Prostate Cancer — Time to Fish or Cut Bait https://t.co/G9Kmvrqrzj

[Adam B. Weiner, MD @Adam_Weiner535]

🚨23 years of PSA screening in @NEJM 🚨

👉ERSPC RCT of >162k patients

📅Median 23 year f/u PSA screening lead to...

📉 #prostatecancer mortality by 13%

✅1 death prevented for every 456 men invited for screening or 12 diagnosed w/ PCa

📉Risk of advanced PCa by 34%

⭐️Benefit continues to rise over time as harm-benefit ratio improves

🔗https://t.co/hGCAfGpmhE

@PCF_Science @PCFnews @urotoday @UrologyTimes @renalandurology @UroOnc

[Tom Powles @tompowles1]

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR&gt; 50% questions unselected surgery

[European Urology @EUplatinum]

📊 Göteborg-1 Trial – 25-Year Follow-up

Extended follow-up from the Göteborg-1 screening trial confirms that active surveillance remains a safe and effective long-term strategy for well-selected men with low- and intermediate-risk prostate cancer.

🔹AS shows 94% PC-specific survival at 25 years (95% CI 91–98%); subgroup CSS at 24 years: 99%/92%/85% (very-low/low/intermediate). Continuous monitoring remains essential.

🔹 Conducted in the pre-MRI era

🔹 Modern imaging and biomarkers may further refine patient selection

📖 European Urology 2025;88:373–380

👉 https://t.co/HHYD2WuOCg

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy

https://t.co/4kndeP56jG

In this phase 2 randomized clinical trial evaluating PSMA-guided intensification of salvage radiotherapy (PSMAiSRT) after radical prostatectomy, 128 patients with biochemical recurrence were randomized to receive either standard-of-care salvage radiotherapy (SRT) or PSMA-PET/CT-guided, lesion-targeted SRT. Over a median follow-up of 37 months, PSMAiSRT significantly improved failure-free survival (HR 0.50, P = .04) and eugonadal failure-free survival (HR 0.45, P = .03), particularly among patients with PSA levels ≥0.3 ng/mL (HR 0.17, P = .01), without increasing toxicity or compromising quality of life.

These findings suggest that PSMA-PET–guided SRT enables isotoxic intensification that enhances cancer control compared with standard imaging–based approaches, warranting confirmation in an ongoing phase 3 trial. #ProstateCancer

@ColinBelliveau_
@taussky
@mbarkati
@AcadianRO

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@nataliagandur
@bavilima